Abstract
Biallelic mutations in the NBS1 gene are responsible for the Nijmegen breakage syndrome (NBS), a rare autosomal recessive disorder characterized by chromosome instability and hypersensitivity to ionising radiation (IR). Epidemiological data evidence that the NBS1 gene can be considered a susceptibility factor for cancer development, as demonstrated by the fact that almost 40% of NBS patients have developed a malignancy before the age of 21. Interestingly, also NBS1 heterozygotes, which are clinically asymptomatic, display an elevated risk to develop some types of malignant tumours, especially breast, prostate and colorectal cancers, lymphoblastic leukaemia, and non-Hodgkins lymphoma (NHL). So far, nine mutations in the NBS1 gene have been found, at the heterozygous state, in cancer patients. Among them, the 657del5, the I171V and the R215W mutations are the most frequently described. The pathogenicity of these mutations is presumably connected with their occurrence in the highly conserved BRCT tandem domains of the NBS1 protein, which are present in a large superfamily of proteins, and are recognized as major mediators of processes related to cell-cycle checkpoint and DNA repair. This review will focus on the current state-of-knowledge regarding the correlation between carriers of NBS1 gene mutations and the proneness to the development of malignant tumours.
Keywords: NBS1, 657del5 mutation, R215W mutation, I171V mutation, IVS11+2insT mutation, heterozygous, cancer predisposition, lymphoma, breast cancer, prostate cancer
Current Genomics
Title: NBS1 Heterozygosity and Cancer Risk
Volume: 9 Issue: 4
Author(s): Alessandra di Masi and Antonio Antoccia
Affiliation:
Keywords: NBS1, 657del5 mutation, R215W mutation, I171V mutation, IVS11+2insT mutation, heterozygous, cancer predisposition, lymphoma, breast cancer, prostate cancer
Abstract: Biallelic mutations in the NBS1 gene are responsible for the Nijmegen breakage syndrome (NBS), a rare autosomal recessive disorder characterized by chromosome instability and hypersensitivity to ionising radiation (IR). Epidemiological data evidence that the NBS1 gene can be considered a susceptibility factor for cancer development, as demonstrated by the fact that almost 40% of NBS patients have developed a malignancy before the age of 21. Interestingly, also NBS1 heterozygotes, which are clinically asymptomatic, display an elevated risk to develop some types of malignant tumours, especially breast, prostate and colorectal cancers, lymphoblastic leukaemia, and non-Hodgkins lymphoma (NHL). So far, nine mutations in the NBS1 gene have been found, at the heterozygous state, in cancer patients. Among them, the 657del5, the I171V and the R215W mutations are the most frequently described. The pathogenicity of these mutations is presumably connected with their occurrence in the highly conserved BRCT tandem domains of the NBS1 protein, which are present in a large superfamily of proteins, and are recognized as major mediators of processes related to cell-cycle checkpoint and DNA repair. This review will focus on the current state-of-knowledge regarding the correlation between carriers of NBS1 gene mutations and the proneness to the development of malignant tumours.
Export Options
About this article
Cite this article as:
Masi di Alessandra and Antoccia Antonio, NBS1 Heterozygosity and Cancer Risk, Current Genomics 2008; 9 (4) . https://dx.doi.org/10.2174/138920208784533610
DOI https://dx.doi.org/10.2174/138920208784533610 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced AI Techniques in Big Genomic Data Analysis
The thematic issue on "Advanced AI Techniques in Big Genomic Data Analysis" aims to explore the cutting-edge methodologies and applications of artificial intelligence (AI) in the realm of genomic research, where vast amounts of data pose both challenges and opportunities. This issue will cover a broad spectrum of AI-driven strategies, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Retrospective Observational Study to Evaluate Causality, Preventability
and Severity of Adverse Drug Reaction Associated with Anticancer Drugs
in a Tertiary Care Hospital in Northern India
Current Drug Safety Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets The Function and Regulation of BMP6 in Various Kinds of Stem Cells
Current Pharmaceutical Design The Role of Quercetin, Flavonols and Flavones in Modulating Inflammatory Cell Function
Inflammation & Allergy - Drug Targets (Discontinued) CAR-NK Cells for Cancer Therapy: Molecular Redesign of the Innate Antineoplastic Response
Current Gene Therapy miRNAs in Gastrointestinal and Liver Cancers: Their Perspectives and Clinical Applications
Current Pharmaceutical Design Respiratory Stem Cells and Progenitors: Overview, Derivation, Differentiation, Carcinogenesis, Regeneration and Therapeutic Application
Current Stem Cell Research & Therapy Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes
Current Pharmaceutical Design The Diterpenoids of the Genus Elaeoselinum (Apiaceae) and their Biological Properties
Current Organic Chemistry miRNAs in Cancer Prevention and Treatment and as Molecular Targets for Natural Product Anticancer Agents
Current Cancer Drug Targets Recent Patents and Patent Applications Relating to mTOR Pathway
Recent Patents on DNA & Gene Sequences Designed Multiple Ligands for Cancer Therapy
Current Medicinal Chemistry Self-Assembling Peptides: Potential Role in Tumor Targeting
Current Pharmaceutical Biotechnology Cellular Delivery In Vivo of siRNA-Based Therapeutics
Current Pharmaceutical Design Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors
Current Medicinal Chemistry Diketoacid Inhibitors of HIV-1 Integrase: From L-708,906 to Raltegravir and Beyond
Current Medicinal Chemistry Synthesis and Enzymological Characterization of Some 2-(Substitutedphenylamino) quinazolin-4(3H)-one Derivatives as Potent α-Glucosidase Inhibitors In Vitro
Letters in Drug Design & Discovery